Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus

Pharmacotherapy

Volumn 29, Issue 12 PART2, 2009, Pages

  Drab, Scott R ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

GLP 1 analog; Glucagon like peptide 1 analog; Liraglutide; Type 2 diabetes mellitus

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CALCITONIN; CHOLESTEROL; EXENDIN 4; FATTY ACID; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEGLITINIDE; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; ORAL ANTIDIABETIC AGENT; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; SULFONYLUREA; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ACUTE PANCREATITIS; ARTICLE; BLOOD PRESSURE REGULATION; CALCITONIN BLOOD LEVEL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIARRHEA; DRUG CLEARANCE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATTY ACID BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; WEIGHT CHANGE; WEIGHT REDUCTION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; DRUG ADMINISTRATION SCHEDULE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 73249152158     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.pt2.43S     Document Type: Article

References (43)

1. Saaddine JB, Cadwell B, Gregg EW, et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med 2006;144:465-74.
2. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002;45:937-48.
3. Tibaldi J. Actions of insulin beyond glycemic control: a perspective on insulin detemir. Adv Ther 2007;24:868-82.
4. Knudsen LB, Kiel D, Teng M, et al. Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc Natl Acad Sci U S A 2007;104:937-42.
5. Nauck MA. Unraveling the science of incretin biology. Am J Med 2009;122:S3-10.
6. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705.
7. Vilsboll T, Agerso H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003;88:220-4.
8. Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes: part II: incretin-based therapy and beyond. Circulation 2008;117:574-84.
9. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002;45:195-202.
10. Amylin Pharmaceuticals. Byetta (exenatide injection) prescribing information. San Diego, CA; 2008.
11. Garber AJ. Glucagon-like peptide-1-based therapies: new developments and emerging data. Diabetes Obes Metab 2008;10:22-36.
12. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-78.
13. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidindione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-30.
14. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84-90.
15. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
16. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): a randomised, 52-week, phase III, double-blind, paralleltreatment trial. Lancet 2008;373:473-81.
17. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs. insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009;52:2046-55.
18. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004;53:1187-94.
19. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the longacting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes
20. Harder H, Nielsen L, Thi TD, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004;27:1915-21.
21. Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes. Diabet Med 2005;22:1016-23.
22. Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a longacting human GLP-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes mellitus. Diabetes Care 2007;30:1608-10.
23. Madsbad S, Krarup T, Deacon CF, Holst JJ. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care 2008;11:491-9.
24. Vilsboll T, Brock B, Perrild H, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med 2008;25:152-6.
25. Garber AJ, Henry R, Ratner R, Hale P, Chang CT, Bode B. Monotherapy with liraglutide, a once-daily human GLP-1 analog, provides sustained reductions in AIC, FPG, and weight compared with glimepiride in type 2 diabetes: LEAD-3 mono 2-year results [abstract]. Diabetes 2009;58:A42.
26. Bode BW, Hale PM, Hammer M, Testa MA, Garber A. Patient reported outcomes in subjects with type 2 diabetes treated with monotherapy regimens of once-daily human GLP-1 analogue liraglutide or glimepiride [abstract]. Diabetologia 2008;51:S357.
27. Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006;114:417-23.
28. Colagiuri S, Frid A, Zdravkovic M, et al. Liraglutide, a human GLP-1 analogue, reduces systolic blood pressure in subjects with type 2 diabetes [abstract]. Diabetologia 2008;51:S360.
29. Courreges JP, Vilsboll T, Zdravkovic M, et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabet Med 2008;25:1129-31.
30. Plutzky J, Garber A, Falahati A, Toft AD, Poulter NR. Metaanalysis demonstrates that liraglutide, a once-daily human GLP-1 analogue, significantly reduces lipids and other markers of cardiovascular risk in T2D. Presented as a poster at the 45th annual meeting of the European association for the study of diabetes (EASD), Vienna, Austria, September 29-October 2, 2009.
31. Edwards CMB, Todd JF, Mahmoudi M, et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 1999;48:86-93.
32. Fehmann HC, Hering BJ, Wolf MJ, et al. The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets. Pancreas 1995;11:196-200.
33. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analog, added to sulfonylurea (SU) offers significantly better glycemic control and favorable weight change compared with rosiglitazone and SU combination therapy in subjects with type 2 diabetes [abstract]. Diabetes 2008;57:A4.
34. Nauck MA, Frid A, Hermansen K, et al. Liraglutide, a oncedaily human glucagon-like peptide-1 analog, in type 2 diabetes provides similar glycemic control with reduced body weight compared with glimepiride when added to metformin [abstract]. Diabetes 2008;57:A150.
35. Freeman JS, Nauck MA, During M, Zdravkovic M, Matthews DR. Transition from oral monotherapy to combination therapy in type 2 diabetes mellitus: comparison of either liraglutide, glimepiride, or placebo, in combination with metformin [abstract]. J Am Osteopath Assoc 2008;108:426.
36. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35.
37. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100.
38. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91.
39. Green BD, Flatt PR. Incretin hormone mimetics and analogues in diabetes therapeutics. Best Pract Res Clin Endocrinol Metab 2007;21:497-516.
40. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009;32:834-8.
41. Vilsboll T. Liraglutide: a new treatment for type 2 diabetes. Drugs Today (Barc) 2009;45:101-13.
42. Frey CF, Zhou H, Harvey DJ, White RH. The incidence and case-fatality rates of acute biliary, alcoholic, and idiopathic pancreatitis in California, 1994-2001. Pancreas 2006;33:336-44.
43. Cappell MS. Acute pancreatitis: etiology, clinical presentation, diagnosis, and therapy. Med Clin North Am 2008;92:889-923.